L6292
赖诺普利
≥98% (HPLC), Angiotensin converting enzyme (ACE) inhibitor., solid
别名:
MK-521, （S）-1- [N2-（1-羧基-3-苯丙基）-赖氨酰脯氨酸 二水合物
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C21H31O5N3 · 2H2O
化学文摘社编号:
分子量:
441.52
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.32
MDL number:
产品名称
赖诺普利, ≥98% (HPLC)
SMILES string
[H]O[H].[H]O[H].NCCCC[C@H](N[C@@H](CCc1ccccc1)C(O)=O)C(=O)N2CCC[C@H]2C(O)=O
InChI
1S/C21H31N3O5.2H2O/c22-13-5-4-9-16(19(25)24-14-6-10-18(24)21(28)29)23-17(20(26)27)12-11-15-7-2-1-3-8-15;;/h1-3,7-8,16-18,23H,4-6,9-14,22H2,(H,26,27)(H,28,29);2*1H2/t16-,17-,18-;;/m0../s1
InChI key
CZRQXSDBMCMPNJ-ZUIPZQNBSA-N
assay
≥98% (HPLC)
form
solid
color
white
solubility
H2O: ≥10 mg/mL
DMSO: ~6.5 mg/mL (with heating and sonicating)
storage temp.
2-8°C
Quality Level
Gene Information
human ... ACE(1636)
正在寻找类似产品? 访问 产品对比指南
Application
赖诺普利已被用于研究杜氏营养不良症小鼠的抗纤维化作用。它已被用于研究经过长期达贝泊汀处理后的 TGR（mRen2）27 （携带小鼠 Ren-2 基因的转基因大鼠）大鼠的肾结构和功能的变化。
Biochem/physiol Actions
血管紧张素转换酶（ACE）抑制剂。
Features and Benefits
该化合物是位于美国新泽西Kenilworth的Merck & Co., Inc.开发。想要浏览其他由制药公司开发的化合物以及已批准药物/候选药物清单， 请单击此处。
signalword
Danger
hcodes
Hazard Classifications
Repr. 1A - STOT RE 2
target_organs
Kidney
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Anne-Roos S Frenay et al.
Journal of the renin-angiotensin-aldosterone system : JRAAS, 13(2), 232-238 (2012-01-28)
Erytropoietin (EPO) has cytoprotective and angiogenic properties and has a beneficial effect in ischaemic conditions. Since the development of renal interstitial abnormalities are often associated with ischaemia, we studied the effects of the long-acting EPO analogue darbepoetin alpha (DA) on
Jason V Baker et al.
PloS one, 7(10), e46894-e46894 (2012-10-20)
Treatments that reduce inflammation and cardiovascular disease (CVD) risk among individuals with HIV infection receiving effective antiretroviral therapy (ART) are needed. We conducted a 2 × 2 factorial feasibility study of lisinopril (L) (10 mg daily) vs L-placebo in combination
Tatjana Ignjatovic et al.
The Journal of biological chemistry, 277(19), 16847-16852 (2002-03-07)
Angiotensin I converting enzyme (kininase II; ACE) inhibitors are important therapeutic agents widely used for treatment in cardiovascular and renal diseases. They inhibit angiotensin II release and bradykinin inactivation; these actions do not explain completely the clinical benefits. We found
Nadir Ulu et al.
The Journal of pharmacology and experimental therapeutics, 345(3), 393-403 (2013-03-27)
Transactivation of epidermal growth factor receptor (EGFR) signaling by G protein-coupled receptors has been implicated in several cardiovascular (CV) conditions, including hypertension, heart failure, and cardiac and vascular hypertrophy. However, the therapeutic potential of EGFR inhibition in these conditions is
Jill A Rafael-Fortney et al.
Circulation, 124(5), 582-588 (2011-07-20)
Nearly universal cardiomyopathy in Duchenne muscular dystrophy (DMD) contributes to heart failure and death. Because DMD patients show myocardial fibrosis well before functional impairment, we postulated that earlier treatment using drugs with antifibrotic effect may be beneficial. Three groups of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持